Hypertension during pregnancy is still an important cause of maternal, fetal and neonatal morbidity and mortality. in physiological conditions, blood pressure usually decreases in the middle of pregnancy (4-6 months of pregnancy) and is on average 15 mmHg lower than before pregnancy. at the end of pregnancy (7-9 months of pregnancy), blood pressure rises again or even exceeds the pre-pregnancy level. This fluctuation is present in normotensive women, in women with a previous history of hypertension, and in women with impending gestational hypertension. The diagnosis of gestational hypertension was previously considered to be made when blood pressure was higher in mid-pregnancy than in early pregnancy (1-3 months of pregnancy) or pre-pregnancy levels; nowadays, it is more likely to be defined based on the absolute value of blood pressure, i.e., systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg. Gestational hypertension is not a single concept and is divided into 3 categories: chronic hypertension, gestational hypertension and pre-eclampsia. Chronic hypertension is defined as hypertension confirmed before pregnancy or present in the first 20 weeks of pregnancy; gestational hypertension is hypertension occurring after 20 weeks of pregnancy without significant proteinuria, and the blood pressure returns to normal at the end of pregnancy. Pre-eclampsia is defined as elevated blood pressure with proteinuria (24-hour urine protein ≥ 300 mg) after 20 weeks of gestation; where severe pre-eclampsia is defined as blood pressure ≥ 160/110 mmHg with massive proteinuria and headache, blurred vision, pulmonary edema, oliguria and abnormal laboratory tests (e.g., decreased platelet count, abnormal liver enzymes), often combined with abnormal placental function. To summarize, hypertension in pregnancy is firstly divided into two categories according to the time of hypertension occurring in the first 20 weeks of pregnancy (i.e. chronic hypertension) and the second 20 weeks of pregnancy (i.e. gestational hypertension, pre-eclampsia), the latter of which is further divided into gestational hypertension (without proteinuria) and pre-eclampsia (with proteinuria) according to the presence or absence of proteinuria. Gestational hypertension, especially chronic hypertension, can adversely affect the prognosis of the mother and the newborn and should be followed closely. Non-pharmacological treatment is usually considered, including strict management, restriction of activity, left lateral position during bed rest, etc. A normal diet without salt restriction, calcium supplementation (2 g/d) and fish oil supplementation are recommended. After receiving non-pharmacological measures, blood pressure is poorly controlled, with levels at ≥150/100 mmHg, pharmacological treatment should be started, with the goal of controlling blood pressure at 130-140/80-90 mmHg. commonly used intravenous drugs include methyldopa, labetalol, magnesium sulfate; oral drugs include beta-blockers or calcium antagonists; of which magnesium sulfate is the The first choice of medication. In particular, ACEI and ARB are teratogenic to the fetus and should not be used in pregnant women or women who are planning to become pregnant. Women with a history of early onset preeclampsia (<28 weeks) may be given low doses of aspirin prophylactically. Pre-eclampsia can develop into a subacute or acute form of hypertension requiring hospitalization, intensive monitoring, early delivery, and the use of parenteral antihypertensives or anticonvulsants. The idea of treatment for gestational hypertension is to first use non-pharmacological treatment, and then consider pharmacological treatment if control is poor. In fact, this is basically the idea for all hypertensive disorders, and attention should be paid to the teratogenic effect of ACEI and ARB on the fetus in gestational hypertension, as well as the prevention, monitoring and treatment of pre-eclampsia.